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ABSTRACT
OS is a severe combined immunodeficiency characterized
by erythrodermia and protracted diarrhea as a result of infil-
tration of oligoclonal-activated T cells, caused by hypomor-
phic mutations in RAGs. The RAG2R229Qmousemodel fully
recapitulates the clinical OS phenotype. We evaluated
whether T and B cell defects, together with the abnormal
lymphoid structure, could affect DC homeostasis and func-
tion. High density of LCs was observed in skin biopsies of
Omenn patients and in the derma of RAG2R229Qmice, cor-
relating with the presence of erythrodermia. In vivomodels
of cutaneous skin painting and CHS demonstrated a de-
creasedmigration of RAG2R229Q DCs—in particular, LCs—
into draining LNs. Interestingly, at steady state, RAG2R229Q
mice showed a reduction in DC number in all hematopoietic
organs except LNs. Analysis of theMHCII marker revealed
a diminished expression also upon the LPS-driven inflam-
matory condition. Despite the decreased number of periph-
eral DCs, BM pre-cDCswere present in normal number
compared with RAG2/ controls, whereas pDCs and
monocytes were reduced significantly. Overall, these re-
sults point to a secondary defect in the DC compartment,
which contributes to clinical manifestations and autoimmu-
nity in OS. J. Leukoc. Biol. 94: 1221–1230; 2013.
Introduction
OS is a genetically inherited disorder characterized by severe
infections, erythrodermia, and protracted diarrhea as a result
of cellular infiltration [1]. Hypomorphic mutations in RAG
genes causing a defective but not abolished variable-diversity-
joining recombination process are the main responsible for
OS, although other genes have been described to cause the
disease [1, 2]. In this context, oligoclonal T cells with a re-
stricted TCR repertoire are generated and undergo homeo-
static proliferation in the periphery as a result of the lym-
phopenic condition, leading to the development of immuno-
pathology. Patients present hypereosinophilia, very few
circulating B cells, hypogamma-globulinemia, but increased
serum IgE [3, 4]. We have described previously a RAG mouse
mutant carrying a hypomorphic mutation in the RAG2 gene
(R229Q), which mimics many of the clinical features of OS.
RAG2R229Q mice show marked infiltration of T lymphocytes
and eosinophils in the skin and gut, which contrasts with the
overall lymphoid depletion observed in thymus, LNs, and
spleen [5, 6]. Similarly to OS patients, RAG2R229Q murine
thymi have abnormal architecture, nearly absent mTEC, and
barely detectable expression of autoimmune regulatory ele-
ments, causing altered negative selection of autoreactive T
cells that escape to the periphery and damage target organs.
Peripheral lymphoid organ architecture is compromised se-
verely [6, 7]. A dramatic decrease in Forkhead p3 nTregs is
observed in humans and mice, indicating impairment in cen-
tral and peripheral tolerance [5, 8]. A still poorly explored
cell compartment in OS is represented by DCs, whose matura-
tion, migration, survival, and production of cytokines are influ-
enced by T cell-derived signals [9–11]. Moreover, the T cell
area contributes to LN architecture, thus influencing DC re-
tention into the LNs [12]. In OS patients, thymic DCs are re-
duced severely and distributed abnormally [13]. Conversely,
DCs are present in OS patients’ skin biopsies [14], and the
accumulation observed in LNs—so-called “dermatopathic reac-
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tion”—is considered a typical clinical feature [15]. Here, we
have investigated whether hypomorphic RAG defects in lym-
phocytes could, in turn, perturb DCs homeostasis, thus con-
tributing to the immune dysregulation observed in OS. The
analysis of the DC subpopulation in thymus, spleen, and pe-
ripheral lymphoid organs of mutant mice shows abnormal sub-
set distribution and alteration in their activation state. More-
over, we demonstrate an impaired DC migration from skin to
the LN at steady state and in inflammatory conditions. These
findings well correlate with our observation of LC accumula-
tion in the skin of OS patients. Overall, these data suggest a
role of RAG2R229Q DCs in the pathogenesis of immunodefi-
ciency and autoimmunity in OS.
MATERIALS AND METHODS
Patients
Human formalin-fixed, paraffin-embedded tissue samples were retrieved from
the archive of the Department of Pathology at Spedali Civili of Brescia (Italy),
in accordance with the protocols of the Spedali Civili of Brescia Institutional
Ethical Board. Skin specimens from Patient 1, who was compound heterozy-
gous in RAG1 gene (R396H/I538fr; named OS4 in ref. [16]), and from Pa-
tient 2, carrying a mis-sense mutation (R229Q) in the RAG2 gene (described
in ref. [17]), were analyzed for the presence of Langerin cells in the epider-
mal and derma layers. Both patients presented typical signs of OS, character-
ized by generalized erythrodermia associated with lymphoadenopathy, failure
to thrive, and eosinophilia.
Mice
129Sv/C57/BL6 Knock-in RAG2R229Q and 129Sv/C57/BL6 RAG2/ mice
were generated as described previously [5]. All animals (8–12 weeks old)
were housed in a specific pathogen-free facility. All procedures were ap-
proved by the Institutional Animal Care and Use Committee (Minister of
Health; Protocol No. 9/2011). All possible efforts were taken to avoid ani-
mal suffering at any stage of the experiments.
FACS and analysis
Single-cell suspensions were obtained from thymus, spleens, LNs, and BM.
Red blood cells were lysed in ACK lysis buffer (Sigma, St. Louis, MO,
USA). Unless otherwise indicated, 106 cells were stained in FACS buffer
with the following mAb purchased by BD PharMingen (San Diego, CA,
USA), or eBioscience (San Diego, CA, USA): CD45 (30-F11, BD
Pharmingen), CD16/32 (93, eBioscience), CD11c (N418, eBioscience),
CD8a (53-6.7, eBioscience), B220 (RA3-6B2, BD Pharmingen), CD11b
(M1/70, eBioscience and BD Pharmingen), Sirp- (CD172a, P84, BD
Pharmingen), PDCA1 (CD317, eBio129C, eBioscience), Siglec H
(eBio440C, eBioscience), Langerin (CD207, EBioL31, eBioscience) [18],
CD115 (AFS98, eBioscience), Ly6C (AL-21, BD Pharmingen), Ly6G (1A8,
BD Pharmingen), MHCII (IAb, M5/114.15.2, eBioscience), CD80 (16-10A1,
BD Pharmingen), CD86 (B7-2, BD Pharmingen), CD40 (3/23, BD
Pharmingen), mouse hematopoietic Lin cocktail (eBioscience), ScaI (D7,
eBioscience), c-Kit (CD117, 2B8, eBioscience), IL-7R (CD127, A7R34,
eBioscience), CD34 (RAM34, eBioscience), CD135 (A2F10, eBioscience),
CD45RA (14.08, BD Pharmingen), CD49b (DX5, eBioscience), and CD19
(1D3, eBioscience). After analyzing pDCs (CD11c, B220, Siglec H,
PDCA1), cDCs were divided in CD8cDCs (CD11c CD8a CD11b) and
CD8cDCs (CD11c CD8 CD11b). In the thymus, cDCs were also identi-
fied as CD8Sirp- or CD8Sirp-. Mo-DCs [19, 20] were identified as
CD11cCD11bCD8Ly6C cells after excluding pDCs and neutrophils
(CD11bLy6G). Where indicated, in LNs, we distinguished: CD11bhi
Langerin, CD8Langerin, skin-derived CD11bloLangerin and CD11b
Langerin, blood-derived LN resident CD8Langerin DCs [21, 22]. In
the BM, we identified: CLPs as LinScaIloCD135IL-7Rckitlo, CMPs as
LinScaIIL-7RcKithiCD16/32loCD34, GMPs as LinIL-7RScaIcKithi
CD16/32hiCD34hi, CDPs as LinIL-7RcKitintCD135CD115hi/lo/, pDCs
as CD11cintDX5CD19CD45RA, monocytes as CD45CD11b Ly6GLy6C,
and precDCs as LinCD11cMHCII [23–25]. The fluorescence-minus-one
correction method was used for all antibodies tested [26]. Samples were
acquired with FACSCanto II System (BD Biosciences), and data were ana-
lyzed with DIVA Software (Version 6.1.3; BD Biosciences) and/or FlowJo
software (Version 7.6.1; TreeStar, Ashland, OR, USA).
BM-DC generation and in vitro characterization
RAG2/ and RAG2R229Q BM cells were flushed, and CD34 precursors
were cultured for 8 days in RPMI 1640 (Lonza, Walkersville, MD, USA)
containing 1% penicillin-streptomycin (Lonza), 5% FBS (Lonza), and 5 
105 M 2-ME (Sigma), and conventional BM-DCs were differentiated with
100 ng/ml human Fms-like tyrosine kinase 3 ligand and 40 ng/ml murine
GM-CSF (PeproTech, Rocky Hill, NJ, USA). RAG2/ and RAG2R229Q con-
ventional BM-DCs were matured with LPS 100 ng/ml for 24 h. IL-12-p70
production by immature and LPS-matured RAG2R229Q and RAG2/ BM-
DCs was evaluated by ELISA (R&D Systems, Minneapolis, MN, USA). For
MLR experiments, splenic BALB/c (Charles River Laboratories, Wilming-
ton, MA, USA) CD90 cells were purified by CD90.2 microbeads (Miltenyi
Biotec, Auburn, CA, USA), and 3  105 T cells were resuspended in 100 l
MLR medium (RPMI 1640, 10% FBS, 50 mM, 2-E) and cocultured with
3  104 RAG2/ and RAG2R229Q immature and LPS-matured BM-DCs,
making 1:3 dilutions in triplicates. After 72 h, 1 Ci 3H (Amersham, Piscat-
away, NJ, USA) was added for 24 h, and 3H incorporation was evaluated by
a liquid scintillator -counter (Wallac Oy 1450 MicroBeta). For in vitro che-
motaxis assay, immature and mature RAG2/ and RAG2R229Q BM-DCs migra-
tion toward selected chemokines was evaluated using a chemotaxis chamber
(Neuroprobe, Pleasanton, CA, USA) and polycarbonate filter (5 m pore size;
Neuroprobe). Cell suspension (50 l; 1.5106 cells/ml) was incubated at 37°C
for 90 min. The stimuli (30 l; 100 ng/mL) were added in the lower cham-
ber, and 50 l DCs (1.5106/ml) were plated in each well. Results were ex-
pressed as the mean number of migrated cells in 5HPF.
In vivo migration of murine DCs
LPS-matured RAG2/ and RAG2R229Q BM-DCs were incubated with 1 M of
the vital dye CFSE (Molecular Probes, Eugene, OR, USA) for 15 min at 37°C.
CFSE-labeled BM-DCs (106 cells) were injected in the left footpad of each
treated mouse, and the contralateral footpad was injected with PBS. After 24
h, popliteal LN draining each footpad was recovered, mechanically disaggre-
gated, enzymatically digested with a mixture of collagenase D (1 mg/ml;
Roche, Mannheim, Germany) and DNAse I (0.4 mg/ml; Roche), and incu-
bated for 30 min at 37°C. The single-cell suspension obtained was counted,
and CD11c/CFSE cells were analyzed by FACS. Dedicated popliteal drain-
ing LNs were mechanically destroyed in 250 l PBS without Ca and Mg
using TissueLyser (Qiagen, Valencia, CA, USA). The resulting homogenate
was centrifuged, and the supernatants were assessed by dedicated ELISA assays
for TNF-, CCL2, CCL17, and CCL21 (R&D Systems).
FITC skin-painting model
Mice were painted on shaved abdomen with 0.2 ml (5 mg/ml) FITC iso-
mer I (Sigma), dissolved previously 50:50 (vol:vol) in acetone:dibutylphta-
late. After 24 and 48 h, inguinal LNs were disaggregated and enzymatically
digested, and CD11c/FITC cells were evaluated by FACS.
CHS reaction
CHS was induced by the hapten OXA (Sigma), freshly prepared at 3% in the
vehicle (acetone:olive oil, 4:1) and painted at Day 5 on the shaved abdomen
for sensitization as follows: 50 l on inguinal LNs, 50 l auxillary and brachial
LNs, and 5 l for on each footpad (20 l/mouse). On Day 0, mice were chal-
lenged by painting the left ear with 1% OXA (20 l) and the right ear with
the vehicle alone. Ear swelling was measured starting from 24 to 72 h after
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painting [27]. At the sacrifice, ears and draining LNs were collected for immu-
nohistochemistry. For FACS analysis, ear-draining LNs were enzymatically di-
gested, and 5  106 cells were stained for LC identification [28].
In vivo LPS stimulation
LPS was injected i.p. (100 ng/g body weight), and mice were killed 6 h
after treatment [29]. To analyze splenic DC exhaustion, LPS (1 g/g body
weight) was injected i.p., and mice were killed after 24, 48, and 72 h [30].
Immunohistochemistry
For single and double immunostains, both fresh-frozen and FFPE tissues have
been used. Five m thick cryostat sections were air-dried and fixed in acetone,
whereas 2 m-thick FFPE sections were dewaxed and rehydrated and endogenous
peroxidase activity blocked by 0.3% H2O2/methanol for 20 min. Heat-induced
antigen retrieval was obtained by microwave treatment or incubation in a thermo-
static bath using EDTA buffer, pH 8.0. As primary antibodies, we used: biotinyl-
ated anti-mouse CD11c (BD PharMingen; 1:100), anti-human CD11c (Monosan,
Uden, Netherlands; 1:50), anti-mouse Langerin (Dendritics, Lyon, France; 1:200),
anti-human Langerin (Vector Laboratories, Burlingame, CA, USA; 1:150), anti-
CD3 (Thermo Scientific, Waltham, MA, USA; 1:100), anti-human CD1a (Dako
Cytomation, Denmark; 1: 50), anti-CD40 (Leica Biosystems, Wetzlar, Germany; 1:
60), anti-DC-LAMP (Instrumentation Laboratory, Werfen Life Group, Bedford,
MA, USA; 1:100), anti-S100 (Dako Cytomation; 1:3000), and anti-BDCA2 (Dendrit-
ics; 1:75). Depending on the primary antibodies used, sections were then incu-
bated with different kits: 4plus Streptavidin HRP Label (Biocare Medical, Con-
cord, CA, USA); Rat-on-Mouse HRP-Polymer (Biocare Medical); real EnVision
rabbit/mouse HRP-labeled polymer system (Dako Cytomation); and MACH 4 AP-
Polymer (Biocare Medical). Reactions were developed in Biocare’s Betazoid DAB
and Ferangi Blue (alkaline phosphatase substrate; Biocare Medical) and counter-
stained with hematoxylin or Methyl Green (Bio-Optica, Milan, Italy). Digital im-
ages were acquired by an Olympus DP70 camera mounted on an Olympus Bx60
microscope, using Cell^F Imaging software (Olympus Soft Imaging System GmbH,
Germany). Langerin cells were counted on different 5HPF (corresponding to 1
mm2 tissue) for each section, selecting areas with the highest number of positive
cells, using the Nikon Eclipse 50i microscope. Values are expressed as number of
cells/mm2.
Statistical analysis
Groups were analyzed with Prism Software (Graph Pad Software, La Jolla, CA,
USA) using unpaired, two-tailed Student’s t-test comparing the experimental
group and control. Data were expressed as mean  sem. A P value 0.05 was
considered significant.
RESULTS
LCs accumulate in the skin of Omenn patients and
RAG2R229Q mice
Skin manifestations represent the clinical hallmark of OS, and
skin eruptions are present frequently in the OS murine counter-
part [5, 6]. LCs have been implicated as aggravators of skin dis-
eases [28, 31] by activating self-antigen-specific T cells and initiat-
ing autoimmune responses [32]. Careful analysis of OS patients’
skin biopsies has revealed an increased number of Langerin
cells in the derma compared with healthy donors (Fig. 1A).
Given the obvious limitations in performing experiments with
tissue samples from Omenn patients, we have addressed the in-
volvement of DCs in OS pathogenesis using the RAG2R229Q mu-
rine model. Interestingly, the majority of Langerin cells was lo-
calized in the derma of mutant mice, and their density increased
considerably in RAG2R229Q skin with severe erythrodermia
(Fig. 1B).
As DCs are involved in the dermatopathic reaction occurring
in OS LNs [15], we further characterized DC subsets in affected
LNs specimens. A predominance of S100 and CD11c LN DCs
was found and within S100 cell subsets, IDCs (S100CD1a
Langerin) and LCs (S100CD1aLangerin), and indetermi-
nate cells (S100CD1aLangerin) were observed [15, 33, 34].
Notably, the most represented S100 DC in OS LN were IDCs
and indeterminate cells, considered as immature precursors of
LCs [35]. These data suggest that IDCs preferentially accumulate
in the LNs, where they might contribute to the dermatopathic
reaction described in OS LNs (Fig. 1B), whereas Langerin cells
remain localized mainly in the derma (Fig. 1A, upper graph).
Normal number of CD11c cells in RAG2R229Q LNs at
steady state and reduced migration in inflammatory
conditions
To understand whether the accumulation of Langerin cells in OS
patients and mouse skin reflects a defect in migration to the LNs, we
have evaluated DCs at steady state and in inflammatory conditions.
At steady state, RAG2R229Q draining LNs, although reduced in size
and cellularity compared with controls [5, 6], showed a normal
number and increased percentage of CD11c DCs evaluated by
FACS analysis (Fig. 2A, left and right). Immunohistochemistry for
CD11c and CD3 showed a similar density of DCs in RAG2R229Q com-
pared with RAG2/ LNs (Fig. 2B). Among DC subsets, only CD8
cDCs were lower in number in RAG2R229Q compared with RAG2/
LNs (Fig. 2C, left). Moreover, we observed an increased frequency of
Mo-DCs [19] (identified as CD11cCD11bCD8B220PDCA1
Ly6GLy6C) in RAG2R229Q LNs (Fig. 2C, right). Interestingly, MH-
CII expression was lower in both cDC subsets (Fig. 2D), and a de-
creased CD80 and CD86 expression was detected in CD8 cDCs
(data not shown). At steady state, LN Langerin subsets were re-
duced numerically compared with controls (Supplemental Fig. 1A).
When we evaluated DC distribution in inflammatory conditions in-
duced by FITC skin painting, we found a reduced number of
FITCCD11c cells at 24 h in RAG2R229Q inguinal LNs, which re-
mained low even at 48 h (Fig. 3A). In particular, both skin-derived
and LN resident Langerin [21, 22] FITC subsets were reduced
(Supplemental Fig. 1B), including the MHCIICD11bloLangerin
subset (Supplemental Fig. 1C). Next, we induced CHS by FITC
(data not shown) or OXA a more powerful hapten [36]. Despite
mutant mice showing a reduced ear thickness (Fig. 3B), Langerin
cells accumulated abnormally in the derma of OXA-stimulated
RAG2R229Q mice (Fig. 3C, lower right) compared with controls (Fig.
3C, upper right), whereas no differences were noticed in vehicle-
treated mice (Fig. 3C, upper and lower left). Importantly, 72 h after
CHS, a reduced number of CD11c DCs were found in RAG2R229Q
ear-draining LNs (Fig. 3D), affecting particularly, the different Lan-
gerin subsets (Fig. 3E). Consistently with OS patients, immunohis-
tochemical analysis did not show an increased recruitment of Lan-
gerin cells in RAG2R229Q ear-draining LNs (data not shown). These
data suggest a defective migration of Langerin cells from the skin
to the LN and a role of LCs in perpetuating skin manifestations in
OS patients and mice, as observed in other autoimmune disorders
[28, 37].
Maina et al. Dendritic cells in Omenn
www.jleukbio.org Volume 94, December 2013 Journal of Leukocyte Biology 1223
Abnormal RAG2R229Q LN structure affects DC
recruitment in inflammatory conditions
To evaluate the functionality of RAG2R229Q DCs, we generated
BM-DCs and tested their function in in vitro assays. RAG2R229Q
BM-DCs did not show defects in the production of IL-12-p70
upon LPS stimulation (Supplemental Fig. 2B). In a MLR assay,
the ability of RAG2R229Q BM-DCs to induce naïve, allogenic T cell
proliferation was comparable with control BM-DCs (Supplemen-
tal Fig. 2C). Moreover, in in vitro chemotaxis assays, mutant im-
mature and mature BM-DCs did not show migratory alterations
in the presence of CCL3, CCL5, and CCL19, respectively (Sup-
plemental Fig. 2D). Next, we evaluated in vivo migration toward
popliteal LNs of CFSE-labeled RAG2/ and RAG2R229Q BM-
DCs, s.c.-injected into the footpad of mutant or control mice. Al-
Figure 1. LCs accumulate in
skin biopsies from OS pa-
tients and mice. (A, upper)
Langerin staining (depicted
in brown) performed on
healthy donor (HD) and OS
patient (Patient 1) skin biop-
sies (upper, middle). (Upper,
right) Double staining for
Langerin (brown) and CD3
(blue) in OS Patient 2 skin
biopsy (original magnifica-
tion, 10; inset original mag-
nification, 20). The upper
graph indicates Langerin
cells/mm2 performed on epi-
dermal and dermal layers
obtained from HDs and OS
patients. (Lower) Immuno-
hystochemical analysis of
Langerin and CD3 cells
performed on the skin of
RAG2/ (left), RAG2R229Q
mice without skin manifesta-
tions (lower, middle panel),
and RAG2R229Q mice with typ-
ical erythrodermia (lower,
right; original magnification,
20). The lower graph shows
absolute counts of Langerin
cells in epidermal and der-
mal layers in RAG2/ ani-
mals and RAG2R229Q mice,
with and without erythroder-
mia. (B) S100, CD1a, Lan-
gerin, and CD11c stainings
on serial sections of the same
LN from an Omenn patient
(Patient 2; original magnifica-
tion, 10; inset original mag-
nification, 20) and a nor-
mal LN.
1224 Journal of Leukocyte Biology Volume 94, December 2013 www.jleukbio.org
though the injection of BM-DCs caused an increase in RAG2/
LN cellularity [38], RAG2R229Q LN cell count remained low as in
untreated mutants (Supplemental Fig. 2E). Consistent with the
atrophic and disorganized OS LN structure [5], the number of
RAG2/ CFSE-labeled BM-DCs isolated from mutant LNs was
reduced compared with BM-DCs retrieved in RAG2/ recipi-
ents, in accordance with data observed in other immunodeficient
mice [39] (Fig. 4A). Our findings indicate that the altered stro-
mal structure of the OS LN has a primary role in determining
the abnormal DC recruitment, despite the high levels of TNF-
found in mutant LNs in response to the inflammatory reaction
caused by DC injection and the slight increase in chemokines
involved in DCs migration [38, 40] (Fig. 4B).
Reduced number and altered distribution of cDCs
and pDCs in RAG2R229Q thymus
We have described previously that human thymic DCs, identified
with CD11c, S100, and BDCA2 immunostainings, were virtually
absent in OS patients, and mature, activated, thymic DCs were
barely detectable, whereas a significant number of CD11c cells
coexpressed CD163, representing macrophages [13]. As defect in
central tolerance has been reported previously in OS patients
and murine counterpart, caused by defective epithelial-thymocyte
cross-talk and aberrant thymic architecture [5, 7, 13], and as DCs
contribute to the clonal deletion of autoreactive T cells and gen-
eration of nTreg cells [41], we have evaluated the DC distribu-
tion and activation state in RAG2R229Q thymi. As a result of the
reduced organ cellularity, RAG2R229Q DCs were increased in fre-
quency, although reduced significantly in number among live
cells (Fig. 5A, left and right). Moreover, DCs were dispersed into
the disorganized thymic structure, and an increased presence of
F4/80 thymic macrophages was observed in the RAG2R229Q cor-
tex (Fig. 5B), similarly to OS patients [13]. Further analysis of
RAG2R229Q DC subsets revealed a significant reduction in number
and frequency of pDCs and CD8 cDCs, whereas CD8 cDCs
were normal in number (Fig. 5C) and higher in frequency (Sup-
plemental Fig. 3A), showing an inversion in the proportion of
RAG2R229Q cDC subsets compared with normal thymus. Recently,
it was found that the cell-surface Sirp- clearly segregates thymic
DCs in two subsets with different localization and function when
costained with CD8 [41]. In RAG2R229Q thymus, CD8Sirp-
“migratory” DCs were more represented in percentage compared
with the same RAG2/ subset and to “thymic resident”
CD8Sirp- RAG2R229Q DCs (Supplemental Fig. 3B). Moreover,
RAG2R229Q CD8Sirp- DCs increased in number compared
with CD8Sirp- (Supplemental Fig. 3C). Remarkably, both
RAG2R229Q cDCs and pDCs displayed a decreased frequency of
MHCII cells (Supplemental Fig. 3D) and a reduced expression
of this marker at single-cell level (Fig. 5D). Moreover, the fre-
quency of CD86-positive cells was reduced significantly compared
with controls (Supplemental Fig. 3D). All of these findings indi-
cate severe alterations in the thymic DC distribution and in the
maturation process.
RAG2R229Q splenic DCs are reduced in number and
show decreased capacity to up-regulate MHCII
expression
Similar to the thymus, the spleens of RAG2R229Q mice, reduced
in size and cellularity [5, 6], showed an increased percentage
but reduced absolute number of CD11c cells (Fig. 6A, left
Figure 2. Abnormal distribution of CD11c subsets in RAG2R229Q LNs. (A) The graphs rep-
resent FACS evaluation of absolute count (left) and frequency (right; **P0.0013) of CD11c
cells in draining LNs in RAG2/ and RAG2R229Q (average of 12 mice, respectively). n., Number.
(B) Immunohistochemistry of CD11c cells (brown) and CD3 cells (blue) on LNs from
RAG2/ and RAG2R229Q mice (left: original magnification, 10; dashed squares represent the
insets shown in the right panels; original magnifications, 40; TT cell area; BB cell area). (C)
Number (left; **P0.001) and frequency distribution (right; *P0.01) of cDCs, pDCs, and Mo-DCs between RAG2/ and RAG2R229Q LN DCs. (D) Mean fluo-
rescence intensity (MFI) of MHCII expression on cDC subsets (**P0.0039).
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and right), which were dispersed into the disorganized struc-
ture and clustered around a very limited number of CD3
cells (Fig. 6B). Among CD11c cells, CD8 cDCs and Mo-DCs
remained numerically normal (Fig. 6C, left) and increased in
frequency (Fig. 6C, right) as the most represented RAG2R229Q
DC populations. Interestingly, the analysis of the MHCII activa-
tion marker showed a lower expression in both cDC subpopu-
lations at steady-state conditions and upon in vivo injection of
LPS [29] (Fig. 6D). The reduction in MHCII expression was
confirmed further in RAG2R229Q BM-DCs induced to differenti-
ate upon LPS stimulation (Supplemental Fig. 2A). Interest-
ingly, in vivo injection of high doses of LPS to induce splenic
DC apoptosis [30] showed that the number of RAG2R229Q DCs
remained nearly constant compared with the reduced number
observed in controls (Fig. 6E). All of these data confirm a per-
turbation in DC distribution and a defective expression of the
Figure 3. Reduced migration of RAG2R229Q
DCs in inflammatory conditions. (A) Evalua-
tion by FACS of the number of CD11c
FITC DCs recruited in inguinal LNs, 24 and
48 h after skin painting (one representative
experiment out of two; five RAG2/ and six
RAG2R229Q mice/group; *P0.0141). (B)
Time course of the response to OXA challenge measured as change in ear thickness (one representative experiment out of two; six mice/group;
**P0.0013; *P0.034; *P0.05). (C) Immunostaining for Langerin (brown) and CD3 (blue) on ears from RAG2/ (upper left) and RAG2R229Q
(lower left) mice, 72 h after challenge with vehicle (acetone:olive oil, 4:1) or RAG2/ (upper right) and RAG2R229Q (lower right), challenged
with OXA. (D) Number of CD11c cells recovered in draining LNs, 72 h after CHS induced by OXA (*P0.0158) and (E) absolute number of
Langerin subsets in draining LNs, identified as described in Materials and Methods (*P0.03; *P0.01).
Figure 4. Reduced migration of RAG2/ CFSE-
labeled BM-DCs into RAG2R229Q popliteal LN.
(A) Evaluation by FACS of the number of
CFSE BM-DCs recovered in popliteal LN, 24 h
after the injection of 106 CFSE-labeled BM-DCs
in the footpad of RAG2/ and RAG2R229Q re-
cipient (Rec.; average of three experiments per-
formed; **P0.0019). (B) TNF- and chemo-
kine quantification by ELISA assays on
RAG2/ and RAG2R229Q LN homogenate, 24 h
after RAG2/ and RAG2R229Q BM-DC injection
(TNF-; *P0.045). UNS, unstimulated.
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activation marker MHCII, also upon LPS induction, which
might contribute to the immune dysregulation in OS.
Normal counts of cDC progenitors and a decreased
number of pDC precursors and monocytes in
RAG2R229Q BM
Next, we evaluated whether the reduced number of DCs in
lymphoid organs could reflect a defect in the number of their
progenitors [23, 24, 42], analyzing RAG2R229Q and age-
matched control BM samples. Interestingly, BM cellularity was
reduced significantly in RAG2R229Q compared with RAG2/
mice (Fig. 7A). No differences in the number of CLPs, CMPs,
GMPs, and CDPs [24, 25] were present in RAG2R229Q BM sam-
ples (Fig. 7B). However, the analysis of DC precursors down-
stream of CDP and GMP revealed a significant decrease in BM
pDCs and monocytes, whereas pre-cDCs [24] were not re-
duced significantly (Fig. 7C). Interestingly, BM-derived pDCs
expressed a lower level of MHCII, even at steady-state condi-
tion (Supplemental Fig. 4A).
DISCUSSION
The peculiar immunophenotype of leaky SCID associated with
autoimmunity, such as OS, represents a unique model to evaluate
the effect of activated T cells on DC distribution and function.
To this end, using the RAG2R229Q mouse model of OS, we have
analyzed the effect of the hypomorphic R229Q RAG mutation in
lymphocytes on the distribution and function of DCs. We noted
in skin biopsies from OS patients an abundance of LCs, which
ectopically accumulated in the dermis. Consistently, the murine
skin showed high density of LCs at steady state, which increased
in inflammatory conditions, correlating with the severity of skin
disease. As LCs are involved in maintaining peripheral tolerance
[43], their ectopic position in the derma could contribute to the
loss of self-tolerance and to the initiation of skin manifestations.
Interestingly, few Langerin cells were found in LNs of OS pa-
tients compared with other subsets involved in the dermatopathic
reaction. In parallel, RAG2R229Q mouse LNs, although reduced in
size and disorganized [5], showed a normal number of all DC
Figure 5. Altered number, distribution, and activation state of
DCs in RAG2R229Q thymus. (A) Absolute number (left; *P
0.0168) and frequency (right; **P0.0016) of RAG2/ (aver-
age of 23 mice) and RAG2R229Q (average of 25 mice) CD11c
cells evaluated by FACS. (B) Immunohistochemistry of DCs
(CD11c, brown) and T cells (CD3, blue; upper) and DCs
(CD11c, brown) and macrophages (F4/80, blue; lower) in
mouse thymi (original magnification, 10; inset original magnifi-
cation, 40; ccortex; mmedulla; *CD11cF4/80 double-
positive cell). (C) Absolute number of DC subsets (one represen-
tative experiment out of four; average of eight RAG2/ and 10
RAG2R229Q mice; ***P0.0001) and (D) mean fluorescence in-
tensity of MHCII expressed by cDCs and pDCs, evaluated by
FACS (*P0.0189; ***P0.0001; *P0.02).
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subsets, with the exception of CD8 cDCs. Moreover, defective
migration of DCs to LNs in inflammatory conditions was demon-
strated by skin painting and the CHS model, in which a reduced
number of cutaneous DCs, in particular Langerin cells, were
found in skin draining LNs. Interestingly, defective LC migration
from skin to LNs and accumulation of LCs in the skin have been
found in autoimmune diseases with cutaneous manifestations,
such as lupus and psoriasis [28, 37]. We speculate that LCs, dislo-
cated into the derma of mutant mice, may activate skin-infiltrat-
ing autoreactive T cells continuously [6, 28], thus perpetuating
chronic skin inflammation. Furthermore, the reduced number of
activated DCs found in draining LNs after cutaneous stimulation
might concur to the reduced migration, although the correlation
between DC maturation and its consequent migration is still con-
troversial [44]. Although chemokines and cytokines have a cru-
cial role in DC development, migration, and function, we did not
detect relevant alterations sustaining the defects observed in our
mutant mice. However, we cannot exclude that in in vivo inflam-
matory conditions, altered production of cytokines and chemo-
kines may play a role in the impaired DC recruitment [45]. Fur-
thermore, the altered OS LN architecture could influence DC
retention, as demonstrated in other immunodeficient mice [12].
This hypothesis is supported by the lack of increase in LN cellu-
larity in mutant mice upon CFSE-labeled BM-DC injection and
the reduced number of CFSE RAG2/ BM-DCs migrated into
mutant LNs. Previous data have indicated the involvement of T
cells in DC maturation [46] and demonstrated DC alterations in
mouse models with defective T cell generation, such as athymic
nu/nu mice [47], ikaros/, and SCID mice [11]. Here, we
showed that thymic DCs in RAG2R229Q mice are reduced in num-
ber and express a lower level of the MHCII surface marker com-
pared with RAG2/ mice. These data well recapitulate the hu-
man phenotype in which a reduced amount of CD11c cells and
absence of CD208 (DC-LAMP), a marker of activated DCs, have
been reported [5, 13]. As thymic DC subsets are involved in neg-
ative selection and mediate nTreg cell induction [41], we hypoth-
Figure 6. Reduced absolute counts, al-
tered subset distribution, decreased
MHCII expression, and altered localiza-
tion of DCs in RAG2R229Q spleen. (A) The
graphs show absolute counts (left;
**P0.0029) and frequency (right;
**P0.003) of splenic RAG2/ (average of
23 mice) and RAG2R229Q (average of 25
mice) CD11c cells evaluated by FACS. (B)
Distribution of CD11c (brown) and CD3
(blue) cells in RAG2/ and RAG2R229Q
spleens evaluated by immunohistochemistry
(original magnification, 10). (C) FACS eval-
uation of number (left; **P0.009;
***P0.0008) and frequency distribution
(right; **P0.0013; **P0.007) of splenic
RAG2/ and RAG2R229Q cDCs, pDCs, and
Mo-DCs (one representative experiment out
of four; average of eight RAG2/ and seven
RAG2R229Q mice). (D) Mean fluorescence
intensity of MHCII expressed by DCs evalu-
ated by FACS in untreated (UNT) mice
(CD8cDCs, *P0.02; CD8cDCs, *P0.03)
and 6 h after LPS treatment (CD8cDCs,
*P0.01; CD8cDCs, **P0.0069; LPS, 100
ng/g mouse weight, i.p.). (E) FACS evalua-
tion of splenic CD11c cell number before
(t0) and after (t24, 48, and 72 h) in vivo
LPS injection (1 g/g mouse weight, i.p.).
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esize that alterations in DC distribution and activation, together
with mTEC deficiency and abnormal thymic structure [5, 6],
could contribute to the defective central tolerance in OS. In addi-
tion, the high density of F4/80 macrophages in murine and
patient thymus [13] might reflect, besides a role in clearance of
apoptotic thymocytes [48, 49], an attempt of macrophages to act
as APCs in the presence of few mTECs and DCs. The analysis of
DC distribution in the spleen has also revealed a marked reduc-
tion in CD8 cDCs and pDCs, whereas CD8 cDCs, including
Mo-DCs [19], were normally represented in number and in-
creased in percentage. MHCII expression level in both cDC sub-
sets was reduced at steady state and upon LPS-induced inflamma-
tory conditions [29]. Interestingly, in vivo injection of high doses
of LPS to induce DC apoptosis [30] showed no variation in the
absolute counts of splenic RAG2R229Q DCs. As the DC number is
crucial for the maintenance of immune homeostasis, we can spec-
ulate that the persistence of RAG2R229Q DCs might contribute to
T cell activation, thus favoring increased susceptibility to autoim-
munity [50, 51]. Furthermore, reduced DC number and activa-
tion state could also affect nTreg cell homeostasis and function
[10]. Indeed, RAGR229Q mice and OS patients showed a severe
reduction in thymic and peripheral nTreg cells and impaired
suppressive functions (refs. [3, 5, 8], and data not shown). When
we evaluated whether the reduced DC counts would be caused by
a defective number of their BM precursors [42], we detected a
normal number of pre-cDCs and a reduction in pDC and mono-
cyte absolute counts. Interestingly, up-regulation of MHCII upon
LPS induction in BM-DCs was impaired, and BM-derived pDCs
expressed a lower level of MHCII even at the steady-state condi-
tion. Of note, RAG genes are expressed in pDCs [52–54]; thus, it
is likely that hypomorphic mutations in RAG genes could also
impair the generation and function of pDCs. Overall, our data
provide, for the first time, evidences of the effect of hypomorphic
mutation in RAG genes on DC distribution and function, thus
adding an additional layer of dysregulation to the mechanisms
controlling central and peripheral tolerance.
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